1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
NeoCore Technology Co., Ltd.

NeoCore Technology Co., Ltd.

4131.TWO
NeoCore Technology Co., Ltd.TW flagTaipei Exchange
32.80
TWD
-0.10
- -
1.31BMarket Cap
NeoCore Technology Co., Ltd.
4131.TWO
(Taipei Exchange)

Recent

price

32.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
2.32
1.96
1.96
2.13
4.07
1.76
1.49
1.1
0.81
3.4
5.5
4.91
4.68
4.68
1.87
1.58
4.86
Revenue per Share
-1.39
-1.79
-1.65
-1.68
-3
-1.44
-1.15
-1.85
-1.42
-1.38
-0.62
-1.43
-0.91
-1.48
-1.87
-1.23
-0.52
Basic EPS, GAAP
-0.3
-1.19
-0.94
-2.58
- -
-8.14
3.51
-1.57
2.47
-1.53
-0.25
-1.47
-0.9
-0.18
-2.18
-1.79
-0.59
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
17.94
16.36
14.83
13.22
13.68
12.24
11.09
9.22
7.8
9.78
8.74
7.31
6.41
4.92
6.76
4.76
7.95
Book Value per Share
18.55
16.11
14.5
12.59
12.81
11.37
10.26
8.73
7.36
8.57
7.62
7.19
5.97
4.1
10.07
7.77
5.86
Tangible Book Value per Share
18
19
19
19
15
15
15
15
15
18
19
19
19
19
35
39
39
Basic Weighted Avg Shares
42
37
37
40
61
27
22
17
12
62
104
93
89
89
65
62
190
Sales/Revenue/Turnover
-74.21
-103.77
-93.89
-97.05
-89.69
-100.61
-86.84
-137.37
-173.86
-41.51
-17.91
-35.17
-31.81
-45.26
-131.18
-123.22
-33.55
Operating Margin (%)
13
12
11
11
9
7
6
4
4
4
8
7
7
7
8
8
25
Depreciation Expense
-25
-34
-31
-32
-45
-22
-17
-28
-21
-25
-12
-27
-17
-28
-65
-48
-20
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-60
-91.13
-84.05
-78.85
-73.66
-81.72
-77.3
-168.29
-174.59
-40.57
-11.36
-29.03
-19.34
-31.71
-99.87
-78.21
-10.76
Profit Margin (%)
199
174
153
126
89
73
63
45
28
78
66
63
42
- -
261
202
84
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
34
32
34
22
43
LT Debt
346
313
283
251
206
184
167
139
118
162
150
141
117
81
351
305
316
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-10.62
-10.56
-11.98
-19.75
-11.11
-9.88
-18.19
-16.66
-16.97
-6.9
-17.77
-13.19
-26.21
-39.48
-22.94
-8.18
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
105
106
115
LT Borrowings
16
- -
- -
LT Finance Leases
46
45
43
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
40
40
Market Capitalization
1,328
1,360
1,292

Working Capital

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
256
271
271
Cash, Cash Equivalents & STI
124
136
124
Accounts Receivable, Net
24
16
25
Inventories
85
101
108
Total Current Liabilities
166
171
188
Payables & Accruals
- -
- -
- -
ST Debt
105
106
115
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.57%
53.38%
-13.15%
Free Cash Flow
166.34%
493.28%
-7.64%
Net Income, GAAP
24.13%
51.9%
-25.54%
Sales/Revenue/Turnover
35.88%
-9.5%
-4.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
20
13
14
18
65
2024
16
18
16
12
62
2025
70
54
55
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.45
-0.39
-0.5
- -
-1.87
2024
-0.4
-0.39
-0.36
- -
-1.23
2025
-0.31
0.31
-0.42
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Tissue Regenix Group plc (TSSNF)
Oncorus, Inc. (ONCR)
XTL Biopharmaceuticals Ltd. (XTLB)
Restart Life Sciences Corp. (HEAL.CN)
OKYO Pharma Limited (OKYO.L)
Biophytis S.A. (BPTS)
Business
NeoCore Technology Co., Ltd. NeoCore Technology Co., Ltd. (4131.TWO) designs, manufactures, and sells biochips and rapid nucleic acid hybridization devices for applications in food safety testing, pathogen detection, and clinical diagnostics. The company's core products include nucleic acid extraction kits, polymerase chain reaction kits, enterovirus identification chips, dairy microbial detection chips, Newcastle disease virus and poultry influenza virus nucleic acid chip testing reagent kits, high-risk human papillomavirus detection chip reagents, and human papillomavirus genotyping test kits for cervical cancer screening; it also provides related rapid hybridization instruments and microfluidic systems to enable high-sensitivity molecular testing. NeoCore Technology operates primarily in Taiwan with manufacturing in Zhunan Science Park, Miaoli County, and serves customers including academic institutions, medical organizations, food manufacturers, and partners in Europe, Asia, and Australia. Founded in 1998 as Dr. Chip Biotechnology Incorporation with headquarters in Tainan City, Taiwan, the company holds ISO9001 and ISO13485 certifications, a GMP license acquired in 2022, and medical equipment registrations from Taiwan's Ministry of Health and Welfare. In 2023, it reorganized and renamed to NeoCore Technology Co., Ltd., reflecting a strategic shift toward diversified biotechnology operations while maintaining focus on biochip innovation; recent advancements include machine upgrades, automation integration, and expanded clinical testing platforms to enhance timeliness and accuracy in early detection.